The invention refers to the use of isoxazole derivatives to prepare medicament able to induce fetal hemoglobin (HbF) synthesis in β-thalassemia and sickle cell disease (SCD) patients.We recently found that isoxazole derivatives characterized by a Resorcinol portion and the C-3 amide moiety show high activity in inducing HbF synthesis in erythroid precursors cells (ErPCs) derived from β-thalassemia patients. These data were verified using ErPCs from an high number of patients with different genotypes and HbF starting levels.
ISOXADOLE DERIVATIVES AS INDUCERS OF FETAL HEMOGLOBIN IN ERYTHROID PRECURSOR CELLS FROM BETA-THALASSEMIC PATIENTS
Lampronti I;Gambari R;
2018
Abstract
The invention refers to the use of isoxazole derivatives to prepare medicament able to induce fetal hemoglobin (HbF) synthesis in β-thalassemia and sickle cell disease (SCD) patients.We recently found that isoxazole derivatives characterized by a Resorcinol portion and the C-3 amide moiety show high activity in inducing HbF synthesis in erythroid precursors cells (ErPCs) derived from β-thalassemia patients. These data were verified using ErPCs from an high number of patients with different genotypes and HbF starting levels.File in questo prodotto:
Non ci sono file associati a questo prodotto.
I documenti in SFERA sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
